Profile data is unavailable for this security.
About the company
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.
- Revenue in CNY (TTM)8.15bn
- Net income in CNY973.25m
- Incorporated1981
- Employees4.62k
- LocationTianjin Pharmaceutical Da Ren Tang Group Corp LtdNo. 17, Baidi Road, Nankai DistrictTIANJIN 300193ChinaCHN
- Phone+86 2 227020892
- Fax+86 2 227020892
- Websitehttp://www.jydrt.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bluestar Adisseo Co | 13.53bn | 327.58m | 27.30bn | 2.73k | 83.34 | 1.81 | -- | 2.02 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 27.31bn | 4.41k | 169.39 | 3.85 | -- | 5.54 | 0.0116 | 0.0116 | 0.3572 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 1.62bn | 487.02m | 29.73bn | 870.00 | 61.04 | 8.15 | -- | 18.34 | 1.08 | 1.08 | 3.60 | 8.10 | 0.4513 | 1.96 | 9.77 | 1,863,318.00 | 13.56 | -6.70 | 14.46 | -7.38 | 94.94 | 96.63 | 30.04 | -49.48 | 8.50 | -- | 0.0006 | -- | 49.22 | 152.37 | 614.22 | -- | 152.72 | -- |
| Gan & Lee Pharmaceuticals | 2.61bn | 386.85m | 30.32bn | 4.48k | 75.87 | 2.78 | -- | 11.62 | 0.6726 | 0.6726 | 4.52 | 18.38 | 0.234 | 0.8926 | 10.97 | 582,412.30 | 3.47 | 8.30 | 3.71 | 8.83 | 72.29 | 85.39 | 14.83 | 26.44 | 7.74 | -- | 0.0006 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.15bn | 973.25m | 31.38bn | 4.62k | 28.05 | 3.91 | -- | 3.85 | 1.27 | 1.27 | 10.60 | 9.09 | 0.744 | 3.12 | 3.24 | 1,765,208.00 | 8.71 | 8.96 | 13.06 | 12.80 | 43.68 | 40.82 | 11.70 | 10.67 | 1.62 | -- | 0.1381 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Humanwell Healthcare Group Co Ltd | 24.67bn | 1.96bn | 33.17bn | 17.68k | 16.84 | 1.89 | -- | 1.34 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Autobio Diagnostics Co Ltd | 4.50bn | 1.30bn | 33.77bn | 5.54k | 25.75 | 3.81 | -- | 7.51 | 2.24 | 2.24 | 7.74 | 15.11 | 0.4066 | 2.08 | 4.27 | 811,768.30 | 11.81 | 12.59 | 14.50 | 15.79 | 64.76 | 61.62 | 29.04 | 26.96 | 2.81 | -- | 0.1035 | 46.40 | 0.0457 | 18.15 | 4.28 | 16.70 | 17.03 | 11.28 |
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 13.84m | 2.45% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 8.73m | 1.54% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2023 | 8.51m | 1.51% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 6.75m | 1.19% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 4.55m | 0.80% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2023 | 3.83m | 0.68% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2023 | 2.97m | 0.52% |
| Hotland Innovation Asset Management Co. Ltd.as of 30 Jun 2023 | 2.64m | 0.47% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2023 | 2.11m | 0.37% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 2.11m | 0.37% |
